AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

Ab 10€ überlege ich es mir zu verkaufen

Verkaufen oder abwarten? Was macht Ihr?

Yes! Die geduldigen werden belohnt :)

7 USD sind ungefähr 6€

Kurs Stuttgart bei 4,52€!?

Thinly traded nano cap Axsome Therapeutics (NASDAQ:AXSM) is up 46% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial, ASCEND, evaluating Fast Track-tagged AXS-05 in patients with major depressive disorder (MDD). The study met the primary endpoint of a statistically significant improvement in depression symptoms as measured by a scale called MADRS compared to bupropion. Specifically, at week 6, patients receiving AXS05, an NMDA receptor antagonist, demonstrated a 17.2-point reduction in MADRS total score versus a 12.1-point reduction for bupropion (p=0.013). At week 6, 47% of patients in the AXS-05 cohort achieved remission compared to 16% for bupropion (p-0.004). Complete data will be submitted for presentation at future medical conferences. A Phase 3 study, STRIDE-1, is in process. Management will host a conference call this morning at 8:30 am ET to discuss the results.

Wieder +40% vorbörslich NASDAQ

Boom ;-)

Axsome Therapeutics (NASDAQ:AXSM) provides year-end clinical update. Phase 3 topline results of AXS-05 in treatment-resistant depression expected in Q1 2019. Phase 3 trial of AXS-07 in acute migraine on track to start in Q1 2019. IDMC recommended Phase 2/3 of AXS-05 in Alzheimer's disease agitation continue AXS-05 treatment arm and no further randomization of bupropion treatment arm; Axsome intends to follow IDMC's recommendation. Phase 2 trial of AXS-12 for treatment of narcolepsy expected to start in January 2019, with topline results in H1 2019. Previously: Phase 2/3 study of Axsome's AXS-05 in AD-related agitation to continue; shares up 23% premarket (Dec. 10)

Thinly traded nano cap Axsome Therapeutics (NASDAQ:AXSM) is up 23% premarket on increased volume following its announcement that its Phase 2/3 clinical trial, ADVANCE-1, evaluating AXS-05 for the treatment of patients with Alzheimer's disease-related agitation will continue as planned. The independent Data Monitoring Committee recommended the continuation based on an unblinded pre-specified futility analysis. It also recommended no further randomization of subjects in the bupropion arm. AXS-05 is an orally available combination of bupropion and dextromethorphan. The role of bupropion, a norepinephrine and dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, is to enhance the bioavailability of dextromethorphan, an NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin and norepinephrine transporters. Previously: Axsome therapeutics to host R&D day focused on AXS-05 and unmet needs in depression, alzheimer’s disease agitation, and nicotine dependence (March 27)

Was geht hier heute? 20% und mehr?

NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that its existing term loan facility agreement with Silicon Valley Bank (SVB) has been amended to provide an additional $4 million growth capital loan, related to Axsome’s narcolepsy clinical program with AXS-12. This additional capital is available to be drawn, at Axsome’s option, subject to the achievement of positive results from the Company’s upcoming Phase 2 trial of AXS-12 in narcolepsy sufficient to proceed to a Phase 3 trial. The financial terms for this additional growth capital are more favorable than those of the original term loan. All other terms and conditions from the original term loan agreement remain in place. “This amendment comes at a relevant time as we prepare to launch our planned Phase 2 trial of AXS-12 in narcolepsy,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Should the results from our Phase 2 trial be positive, this optional funding mechanism provides us with flexibility to quickly proceed to the next stages of our clinical development plan for AXS-12.” The additional $4 million growth capital loan must be drawn by May 31, 2019 and will bear interest at an annual rate equal to the greater of the prime rate plus 2.00%, or 7.25%, if drawn. Axsome issued warrants to purchase 63,000 shares of Axsome common stock concurrent with the signing of this amendment, of which 15,750 are earned immediately. The warrants to purchase the remaining 47,250 shares of Axsome common stock will be earned upon the funding of the additional growth capital loan. Additional details of the loan amendment will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K.

Axsome Therapeutics (NASDAQ:AXSM) has hit the enrollment target in its Phase 2 clinical trial, ASCEND, evaluating AXS-05 in patients with major depressive disorder (MDD). Topline data should be available in January 2019.

seltsam... dabei stehen ein paar interessante Termine Ende 2018 an und q1 2019

Wow was los hier?

NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2018 on Friday, November 9, 2018 before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 AM Eastern Time on November 9, 2018 to discuss these results and provide a business update. To participate in the live conference call, please dial (844) 698-4029 (toll-free domestic) or (647) 253-8660 (international) and use the conference ID 9186796. A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. A recording of the conference call will be available on the Company’s website for approximately 30 days following the live event.